It is now well documented that substantial disparities exist in the quality and quantity of
medical care received by minority Americans, especially those of African, Asian and …

Background: Activation of the sympathetic nervous system (SNS) has been linked to
hypertension. Beta-blockers, which decrease SNS activation via β-adrenergic receptor …

Although well established in treating hypertension and cardiovascular (CV) disease, clinical
trial data suggest that β-blockers (eg, atenolol) may be less effective than other …

Hypertension is a leading cause of morbidity and mortality in the United States. Associated
with the long-term consequences of strokes, heart disease, and renal failure, hypertension …

Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has
expanded and become better defined. Labetalol is an adrenoceptor blocking drug with …

Hypertension is the most common public health challenge in the United States because of
its prevalence and associated increase in comorbid cardiovascular diseases 1. Yearly …

Beta adrenergic receptor blockers (β‐blockers) are an important class of drugs in the
management of patients with cardiovascular diseases. These drugs have been shown to …

This article contrasts the characteristics of essential hypertension found in the black
population with that seen in the nonblack population. Socioeconomic and pathophysiologic …

Women are underrepresented in clinical trials. Lower doses of beta-blockers are required for
Southeast Asians. ACE and ARB's are teratogenic in the second trimester. Torsades de …

Beta-adrenergic blockade is established therapy in the management of both hypertension
and angina pectoris. This review evaluates the use of combined alpha-adrenergic and beta …